Rapid Reshore & Development and BrainStorm Cell Therapeutics Announce Agreement to Advance Construction of BrainStorm’s US Manufacturing Facility…

PHILADELPHIA and NEW YORK, Oct. 26, 2020 /PRNewswire/ --Rapid Reshore & Development (RR&D), an alliance of three specialized firms, and BrainStorm Cell Therapeutics, Inc (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced that BrainStorm has selected RR&D as its partner toexpedite site selection and design services for a state-of-the-art manufacturing facility for NurOwn (autologous MSC-NTF) in the U.S.

BrainStorm is investigating NurOwn as a potential treatment for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). BrainStorm's most advanced clinical program for NurOwn is in ALS, which is currently being evaluated in a pivotal Phase 3 clinical trial.

BrainStorm seeks to locate, design and construct a new commercial manufacturing facility in the U.S. to prepare for potential commercialization. RR&D, a three-firm services alliance consisting of EwingCole, Facility Logix and Biggins, Lacy, Shapiro & Company, will identify the location and develop the design of BrainStorm's new commercial manufacturing facility.

"We're thrilled to be working with BrainStorm on this project and to have the opportunity to deliver this critical work to our region," said EwingCole CEO, Jared Loos, PE, AIA. "We embrace the spirit of creating potentially life-changing technology and we will do everything we can to move the project forward in an efficient and yet responsible manner."

BrainStorm intends to use the facility primarily for cell therapy production. RR&D will provide custom, streamlined project management, site selection analysis and design/construction management services throughout the project's lifecycle.

Chaim Lebovits, Chief Executive Officer of BrainStorm Cell Therapeutics commented, "Our decision to partner with RR&D was driven by the strong capabilities of the individual partners and their holistic approach to planning, site selection and design services. The expansion of BrainStorm's manufacturing capabilities is a key part of our broader corporate strategy to prepare for potential regulatory approvals of NurOwn and becoming a commercial organization. This new partnership follows our recently announced agreement with Catalent Pharma Solutions to manufacture NurOwn at a scale large enough to meet potential commercial needs at the time of launch. The dedicated, state-of-the-art manufacturing facility developed by RR&D will provide us with important long-term autonomy and strategic flexibility, including the capacity to supply NurOwn for additional disease indications beyond ALS. Together these two partnerships will help ensure that BrainStorm has the manufacturing capacity to meet the needs of patients today and well into the future."

Site selection analyses will begin immediately with the goal of identifying locations that offer a cost-effective solution for BrainStorm's new manufacturing facility. At the same time, the design team will begin developing a conceptual design of the manufacturing facility, based upon input from BrainStorm's process, engineering, and scientific staff, by defining the main steps of the production process and Current Good Manufacturing Practices (cGMP) requirements. The approximately 50,000 square-foot building will contain manufacturing suites, complementary support and infrastructure, and the ability to expand the facility to 100,000 square feet to anticipate future programmatic needs.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc.is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from theU.S. Food and Drug Administration(FDA) and theEuropean Medicines Agency(EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at sixU.S.sites supported by a grant from theCalifornia Institute for Regenerative Medicine(CIRM CLIN2-0989). The pivotal study is intended to support a filing forU.S.FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently receivedU.S.FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS). The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) completed enrollment inAugust 2020. For more information, visit the company's website atwww.brainstorm-cell.com.

About Rapid Reshore & Development:

Rapid Reshore & Development is an alliance of expert firms providing confidence and support throughout the life sciences industry, representing an evolution from transaction-driven service models to a holistic focus on client needs, integrating an interdisciplinary team customized for a variety of individual projects. To optimize and strengthen confidence in decision-making and speed-to-market, Rapid Reshore & Development alliance was formed to deliver best-in-class professionals with deep experience in all aspects of life sciences' project planning, site selection, design and execution including financial, labor market, development incentives, real estate, design and engineering, and construction management.For additional information, visit: http://www.rapidreshore.com

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm's need to raise additional capital, BrainStorm's ability to continue as a going concern, regulatory approval of BrainStorm's NurOwn treatment candidate, the success of BrainStorm's product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm's NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm's ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm's ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Brainstorm:Investor Relations: Corey Davis, Ph.D. LifeSci Advisors, LLC Phone: +1 646-465-1138 [emailprotected]

Media:Paul Tyahla SmithSolve Phone: + 1.973.713.3768 [emailprotected]

Rapid Reshore & Development (RR&D):Media Contact:Zachary DeRitis Communications Specialist 215-409-4249 [emailprotected]

SOURCE BrainStorm Cell Therapeutics Inc.; Rapid Reshore & Development (RR&D)

See the original post here:
Rapid Reshore & Development and BrainStorm Cell Therapeutics Announce Agreement to Advance Construction of BrainStorm's US Manufacturing Facility...

3D Cell Culture Market 2020 Share, Size, Future Demand, Global Research, Top Leading player, Emerging Trends, Region by Forecast to 2027, Analysis by…

The Global 3D Cell Culture Market report offers key insights into the worldwide 3D Cell Culture market. It presents a holistic overview of the market, with an in-depth summary of the markets leading players. The report is inclusive of indispensable information related to the leading competitors in this business sector and carefully analyzes the micro- and macro-economic market trends. The latest report specializes in studying primary and secondary market drivers, market share, the leading market segments, and comprehensive geographical analysis. Vital information about the key market players and their key business strategies, such as mergers & acquisitions, collaborations, technological innovation, and trending business policies, is one of the key components of the report.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1333

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

Advanced Biomatrix, 3D Biotek, corning Incorporated, Becton and Dickinson Company (BD), Thermo Fisher scientific Inc., Global cell solutions Inc., Nanofiber solutions, VWR Corporation, Synthecon incorporated, Lonza Group Ltd., and Tecan Trading AG., among others.

Furthermore, our market analysts have drawn focus to the significant impact of the COVID-19 pandemic on the global 3D Cell Culture market and its key segments and sub-segments. The grave aftereffects of the pandemic on the global economy, and subsequently, on this particular business sphere, have been enumerated in this section of the report. The report considers the key market-influencing parameters, delivering a detailed future impact assessment. The 3D Cell Culture market has been devastated by the pandemic, which has culminated in drastic changes to the market dynamics and demand trends.

Technology Outlook (Revenue, USD Billion; 2018-2026)

Application Outlook (Volume, Kilo tons; 2018-2026 And Revenue, USD Billion; 2018-2026)

End users Outlook (Volume, Kilo tons; 2018-2026 And Revenue, USD Billion; 2018-2026)

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1333

Moreover, the research report thoroughly examines the size, share, and market volume of the 3D Cell Culture industry in the historical years to forecast the same valuations over the forecast duration. It offers exhaustive SWOT analysis, Porters Five Forces analysis, feasibility analysis, and investment return analysis of the 3D Cell Culture market, assessed using certain effective analytical tools. The report also provides strategic recommendations to market entrants to help them navigate around the entry-level barriers.

The global 3D Cell Culture market is geographically categorized into:

The following timeline is considered for market estimation:

Historical Years: 2017-2018

Base Year: 2019

Estimated Year: 2020

Forecast Years: 2020-2027

Key Coverage of the Report:

To read more about the report, visit@ https://www.reportsanddata.com/report-detail/3d-cell-culture-market

Thank you for reading our report. For further information or queries regarding the report, please get in touch with us. Our team will make sure your report is tailored according to your requirements.

About Us:

Our in-house experts assist our clients with advice based on their proficiency in the market that helps them in creating a compendious database for the clients. Our team offers expert insights to clients to guide them through their business ventures. We put in rigorous efforts to keep our clientele satisfied and focus on fulfilling their demands to make sure that the end-product is what they desire. We excel in diverse fields of the market and with our services extending to competitive analysis, research and development analysis, and demand estimation among others, we can help you invest your funds in the most beneficial areas for research and development. You can rely on us to provide every significant detail you might need in your efforts to make your business flourish.

Contact Us:

John Watson

Head of Business Development

Reports and Data|Web: http://www.reportsanddata.com

Direct Line:+1-212-710-1370

E-mail: [emailprotected]

Follow this link:
3D Cell Culture Market 2020 Share, Size, Future Demand, Global Research, Top Leading player, Emerging Trends, Region by Forecast to 2027, Analysis by...

Totipotent Stem Cell Market Report Provide the Development Strategies Adopted by Key Industry Players to Understand Competitive Scenario of the Global…

The global Totipotent Stem Cell market 2020 mainly focuses on the market trend, market share, size and forecast. It is a brief and professional analysis on the current scenario of the Global Totipotent Stem Cell market.

The report on Totipotent Stem Cell market is a comprehensive study on global market analysis and insights. The report focuses on the emerging trends in the global and regional spaces on all the significant components, such as market capacity, cost, price, demand and supply, production, profit, and competitive landscape. The report analyzes past trends and future prospects in this report which makes it highly comprehensible for the analysis of the market. Moreover, the latest trends, product portfolio, demographics, geographical segmentation, and regulatory framework of the Totipotent Stem Cell market have also been included in the study.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.researchmoz.com/enquiry.php?type=S&repid=2618828&source=atm

What the Totipotent Stem Cell market research report basically consists of?

The report gives a look at the recent developments and their innovations in the global Totipotent Stem Cell

The report presents the basic overview of the industry which includes the definition, manufacturing along with its applications.

The report mainly comprises the recent marketing factors that are crucial to keep an eye on to analyze the market performance to fuel the profitability and productivity of the industry.

The report enhances its focus on the estimates of 2020-2026 market development trends of the Global Totipotent Stem Cell

Furthermore, an analysis of arduous raw materials, demand and production value has been laid out.

Market segmentation:

Research analysts have studied and analyzed the report on these 3 segments which cover the market share, revenues, growth rate along with the other factors that uplift the growth rate in Global Totipotent Stem Cell market. This study will lead in identifying the high growth areas as well as in identifying the growth factors which are helping in leading these segments.

The major players profiled in this report include: Company A

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2618828&source=atm

This research is a comprehensive way to understand the current landscape of the market, especially in 2020. Both top-down and bottom-up approaches are employed to estimate the complete market size. This will help all the market stakeholders to have a better understanding of the direction in which the market will be headed and future forecast.

The end users/applications and product categories analysis: On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into- General Type

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Totipotent Stem Cell for each application, including- Medical

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2618828&licType=S&source=atm

Reasons to purchase this report:

It provides market dynamics scenario along with growth opportunities in the forecast period.

It determines upcoming opportunities, threats and obstacles that can have an effect on the industry.

This report will help in making accurate and time bound business plans keeping in mind the economic shift.

To interpret the market competitive advantages of the industry as well as internal competitors.

To enhance the creation long term business plans.

Regional and country level analysis.

Segment wise market value and volume.

SWOT, PEST analysis along with the strategies adopted by major players.

Table of Content

1 Market Overview

1.1 Totipotent Stem Cell Introduction

1.2 Market Analysis by Type

1.2.1 Overview: Global Totipotent Stem Cell Revenue by Type: 2015 VS 2019 VS 2025

1.2.2 Coat/Jacket

1.2.3 Pants

1.2.4 Vest

1.3 Market Analysis by Application

1.3.1 Overview: Global Totipotent Stem Cell Revenue by Application: 2015 VS 2019 VS 2025

1.3.2 Indoor Firefighting

1.3.3 Wild Firefighting

1.3.4 Marine Firefighting

1.3.5 Others

1.4 Overview of Global Totipotent Stem Cell Market

1.4.1 Global Totipotent Stem Cell Market Status and Outlook (2015-2025)

1.4.2 North America (United States, Canada and Mexico)

1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)

1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

1.4.5 South America, Middle East & Africa

1.5 Market Dynamics

1.5.1 Market Opportunities

1.5.2 Market Risk

1.5.3 Market Driving Force

2 Manufacturers Profiles

3.3 Market Concentration Rate

3.3.1 Top 3 Totipotent Stem Cell Manufacturer Market Share in 2019

3.3.2 Top 6 Totipotent Stem Cell Manufacturer Market Share in 2019

3.4 Market Competition Trend

4 Global Market Analysis by Regions

4.1 Global Totipotent Stem Cell Sales, Revenue and Market Share by Regions

4.1.1 Global Totipotent Stem Cell Sales and Market Share by Regions (2015-2020)

4.1.2 Global Totipotent Stem Cell Revenue and Market Share by Regions (2015-2020)

4.2 North America Totipotent Stem Cell Sales and Growth Rate (2015-2020)

4.3 Europe Totipotent Stem Cell Sales and Growth Rate (2015-2020)

4.4 Asia-Pacific Totipotent Stem Cell Sales and Growth Rate (2015-2020)

4.5 South America Totipotent Stem Cell Sales and Growth Rate (2015-2020)

4.6 Middle East and Africa Totipotent Stem Cell Sales and Growth Rate (2015-2020)

5 North America by Country

5.1 North America Totipotent Stem Cell Sales, Revenue and Market Share by Country

5.1.1 North America Totipotent Stem Cell Sales and Market Share by Country (2015-2020)

5.1.2 North America Totipotent Stem Cell Revenue and Market Share by Country (2015-2020)

5.2 United States Totipotent Stem Cell Sales and Growth Rate (2015-2020)

5.3 Canada Totipotent Stem Cell Sales and Growth Rate (2015-2020)

5.4 Mexico Totipotent Stem Cell Sales and Growth Rate (2015-2020)

6 Europe by Country

6.1 Europe Totipotent Stem Cell Sales, Revenue and Market Share by Country

6.1.1 Europe Totipotent Stem Cell Sales and Market Share by Country (2015-2020)

6.1.2 Europe Totipotent Stem Cell Revenue and Market Share by Country (2015-2020)

6.2 Germany Totipotent Stem Cell Sales and Growth Rate (2015-2020)

6.3 UK Totipotent Stem Cell Sales and Growth Rate (2015-2020)

6.4 France Totipotent Stem Cell Sales and Growth Rate (2015-2020)

6.5 Russia Totipotent Stem Cell Sales and Growth Rate (2015-2020)

6.6 Italy Totipotent Stem Cell Sales and Growth Rate (2015-2020)

7 Asia-Pacific by Regions

7.1 Asia-Pacific Totipotent Stem Cell Sales, Revenue and Market Share by Regions

7.1.1 Asia-Pacific Totipotent Stem Cell Sales and Market Share by Regions (2015-2020)

7.1.2 Asia-Pacific Totipotent Stem Cell Revenue and Market Share by Regions (2015-2020)

7.2 China Totipotent Stem Cell Sales and Growth Rate (2015-2020)

7.3 Japan Totipotent Stem Cell Sales and Growth Rate (2015-2020)

7.4 Korea Totipotent Stem Cell Sales and Growth Rate (2015-2020)

7.5 India Totipotent Stem Cell Sales and Growth Rate (2015-2020)

7.6 Southeast Asia Totipotent Stem Cell Sales and Growth Rate (2015-2020)

7.7 Australia Totipotent Stem Cell Sales and Growth Rate (2015-2020)

8 South America by Country

8.1 South America Totipotent Stem Cell Sales, Revenue and Market Share by Country

8.1.1 South America Totipotent Stem Cell Sales and Market Share by Country (2015-2020)

8.1.2 South America Totipotent Stem Cell Revenue and Market Share by Country (2015-2020)

8.2 Brazil Totipotent Stem Cell Sales and Growth Rate (2015-2020)

8.3 Argentina Totipotent Stem Cell Sales and Growth Rate (2015-2020)

9 Middle East & Africa by Countries

9.1 Middle East & Africa Totipotent Stem Cell Sales, Revenue and Market Share by Country

See the article here:
Totipotent Stem Cell Market Report Provide the Development Strategies Adopted by Key Industry Players to Understand Competitive Scenario of the Global...

Apellis and Sobi Enter Collaboration for Global Co-development and Ex-US Commercialization of Systemic Pegcetacoplan in Rare Diseases with Urgent Need…

Details Category: Proteins and Peptides Published on Tuesday, 27 October 2020 18:20 Hits: 241

WALTHAM, MA, USA and STOCKHOLM, Sweden I October 27, 2020 I Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO:SOBI) today announced a strategic collaboration to accelerate the advancement of systemic pegcetacoplan, a targeted C3 therapy, for the treatment of multiple rare diseases with high unmet need that impact more than 275,000 patients globally.

Sobi will receive global co-development and exclusive ex-US commercialization rights for systemic pegcetacoplan. Apellis retains U.S. commercialization rights for systemic pegcetacoplan and worldwide commercial rights for ophthalmological pegcetacoplan, which is being evaluated by Apellis in two fully enrolled Phase 3 studies in geographic atrophy (GA). Pegcetacoplan targets excessive activation of C3 in the complement cascade, part of the bodys immune system, which can lead to the onset and progression of many serious diseases.

Apellis and Sobi plan to jointly advance the clinical development of systemic pegcetacoplan in five parallel registrational programs across hematology, nephrology, and neurology. These include new registrational programs in cold agglutinin disease (CAD) and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA), both of which are expected to start in 2021. By controlling complement activation centrally, pegcetacoplan offers the potential to become a transformative new therapy in several rare diseases where patients have few or no treatment options today.

This collaboration enables us to further expand on the broad platform potential of targeting C3 for serious rare diseases that impact hundreds of thousands of patients around the world, said Cedric Francois, M.D., Ph.D., co-founder and chief executive officer of Apellis. We evaluated numerous companies, medium and large, and chose Sobi because of their global leadership in hematology and rare diseases, track record of successful product launches, and deep commitment to patients. Together, we will quickly advance systemic pegcetacoplan in multiple registrational programs across hematology, nephrology, and neurology while also preparing for our first potential U.S. launch in PNH. Financially, this transaction also strengthens our position, with our cash runway expected to extend into the second half of 2022.

We are excited to collaborate with Apellis, a leader in targeted C3 therapies. The collaboration will significantly strengthen and broaden our late-stage R&D portfolio and be a catalyst for further internationalization. The products have an excellent fit with our strategic focus on hematology and immunology, said Guido Oelkers, chief executive officer and president of Sobi. Given the central role of C3 in the complement cascade, pegcetacoplan has the potential to become the foundation for a broader platform in rare diseases. With positive Phase 3 data in PNH, pegcetacoplan can elevate the standard of care for this debilitating blood disorder.

As part of the collaboration, Apellis and Sobi will co-develop systemic pegcetacoplan in the following rare diseases:

Hematology Paroxysmal nocturnal hemoglobinuria (PNH), CAD, and HSCT-TMA PNH represents the first potential indication to market for systemic pegcetacoplan. Marketing applications for pegcetacoplan for the treatment of PNH were submitted to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) based on positive results from the Phase 3 PEGASUS study. Top-line results from the Phase 3 PRINCE study, which is evaluating pegcetacoplan in treatment-nave patients with PNH, are expected in the first half of 2021.

Sobi will lead development activities for the Phase 3 study in CAD and a potentially registrational Phase 2 study in HSCT-TMA, both planned to start in 2021.

Nephrology Immune complex membranoproliferative glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G) Apellis has initiated and will continue to lead a registrational program in IC-MPGN and C3G, which includes Phase 2 and Phase 3 studies.

Neurology Amyotrophic lateral sclerosis (ALS) Apellis has initiated and will continue to lead a potentially registrational Phase 2 study in ALS. Multiple other neurological conditions are under consideration for future clinical development.

About the Transaction Sobi will make an upfront payment of $250 million to Apellis and up to $915 million in other regulatory and commercial milestone payments, and will contribute $80 million in reimbursement payments over a four-year period for research and development to support the initial development plan, which includes ongoing studies in PNH, IC-MPGN/C3G, and ALS and new studies in CAD and HSCT-TMA. Apellis will also be eligible for tiered double-digit royalties on sales ranging from high teens to high twenties. Sobi intends to finance these payments with available funds. Sobi will receive reimbursement payments for the costs incurred by Sobi in connection with the CAD and HSCT-TMA trials that Sobi will conduct. The parties have agreed to split costs 50/50 for any future global studies beyond the initial development plan.

Per the terms of the agreement, Apellis will be responsible for all regulatory and commercial activities in the United States and the ongoing Marketing Authorization Application (MAA) review for PNH in the European Union, which will be subsequently transferred to Sobi. Sobi will be responsible for regulatory and commercial activities for systemic pegcetacoplan in ex-US markets. The co-development of systemic pegcetacoplan will be overseen by a joint development committee, and the commercial strategy will be overseen by a joint commercial committee.

Conference Call and Webcast Apellis will host a conference call and webcast to discuss its collaboration with Sobi today, October 27, 2020, at 8:30 a.m. ET. To access the conference call, please dial (866) 774-0323 (local) or (602) 563-8683 (international) at least 10 minutes prior to the start time and refer to conference ID 5774165. A live audio webcast of the event and accompanying slides may also be accessed through the Events and Presentations page of the Investors and Media section of the companys website at http://investors.apellis.com/events-and-presentations. A replay of the webcast will be available for 30 days following the event.

About Pegcetacoplan (APL-2) Pegcetacoplanis an investigational, targeted C3 therapy designed to regulate excessive complement activation, which can lead to the onset and progression of many serious diseases.Pegcetacoplanis a synthetic cyclic peptide conjugated to a polyethylene glycol polymer that binds specifically to C3 and C3b.Apellis is evaluatingpegcetacoplanin several clinical studies across hematology, ophthalmology, nephrology, and neurology.Pegcetacoplanwas granted Fast Track designation by the U.S. Food and Drug Administration (FDA) forthe treatment of PNH and the treatment of geographic atrophy and received orphan drug designation for the treatment of C3G by the FDA and European Medicines Agency.

About Pegcetacoplan for Paroxysmal Nocturnal Hemoglobinuria (PNH) In October, the European Medicines Agency validated the Marketing Authorization Application (MAA) for pegcetacoplan in PNH, and an opinion from the Committee for Medicinal Products for Human Use is expected in 2021. A decision by the U.S. Food and Drug Administration regarding the acceptance of the New Drug Application (NDA) and a Prescription Drug User Fee Act (PDUFA) target action date is expected in the fourth quarter of 2020. Top-line results from the Phase 3 PRINCE study, which is evaluating pegcetacoplan in treatment-nave patients with PNH, are expected in the first half of 2021.

The NDA and MAA submissions for pegcetacoplan for the treatment of PNH are based on positive results from the Phase 3 PEGASUS study (APL2-302; NCT03500549), a multi-center, randomized, active-comparator controlled Phase 3 study in 80 adults with PNH. The primary objective of PEGASUS was to establish the efficacy and safety of pegcetacoplan compared to eculizumab. Pegcetacoplan is also being evaluated in the Phase 3 PRINCE study (APL2-308; NCT04085601), a randomized, multi-center, controlled study evaluating pegcetacoplan in 53 patients with PNH who had not received a complement inhibitor within three months before entering the study.

AboutPNH PNH is a rare, chronic, life-threatening blood disorder characterized by the destruction of oxygen-carrying red blood cells through extravascular and intravascular hemolysis. Persistently low hemoglobin can result in frequent transfusions and debilitating symptoms such as severe fatigue, hemoglobinuria, and difficulty breathing (dyspnea). A retrospective analysis shows that, even on eculizumab, approximately 72% of people with PNH have anemia, a key indicator of ongoing hemolysis.1 The analysis also finds that 36% of patients require one or more transfusions a year and 16% require three or more.1

About Cold Agglutinin Disease (CAD) CAD is a severe, chronic, rare blood disorder2 that currently has no approved therapies and impacts ~10,500 people across the United States and Europe.3 People living with CAD may suffer from chronic anemia, transfusion requirements, and an increased risk of life-threatening thrombotic events such as stroke.4 In people with CAD, immunoglobin M (IgM) autoantibodies cause red blood cells to agglutinate, or clump together, at temperatures below 30oC or as a result of a compromised immune system or infection.5 This activates the complement cascade to destroy healthy red blood cells through extravascular and intravascular hemolysis.6,7

About Hematopoietic Stem Cell Transplantation Thrombotic Microangiopathy (HSCT-TMA) HSCT-TMA is rare blood disease that can be a fatal complication of a bone marrow transplant or HSCT.8 In HSCT-TMA, microscopic blood clots form in small blood vessels, leading to organ damage. The kidneys are commonly affected, although any organ may be involved.8 HSCT-TMA occurs in up to 40% of HSCT recipients;9 every year, there are ~9,000 allogeneic transplants in the United States and ~18,000 in the EU+.10,11 Excessive complement activation is a high-risk feature in patients with HSCT-TMA,12 and C3 is believed to play a critical role in TMA based on proinflammatory and procoagulant properties of C3a and C3b.13

About Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) and C3 Glomerulopathy (C3G) IC-MPGN and C3G are rare, debilitating kidney diseases that affect ~18,000 people in the United States and Europe.14 There are no approved therapies for the diseases, and symptoms include blood in the urine, dark foamy urine due to the presence of protein, swelling, and high blood pressure.15 Approximately 50% of people living with IC-MPGN and C3G ultimately suffer kidney failure within five to 10 years of diagnosis.16 Although IC-MPGN is considered a distinct disease from C3G, the underlying cause and progression of the two diseases are remarkably similar and include overactivation of the complement cascade, with excessive accumulation of C3 breakdown products in the kidney causing inflammation and damage to the organ. 17,18

About Amyotrophic Lateral Sclerosis (ALS) ALS is a devastating neurodegenerative disease that results in progressive muscle weakness and paralysis due to the death of nerve cells, called motor neurons, in the brain and spinal cord.19, 20 The death of motor neurons leads to theprogressive loss of voluntary muscle movement required forspeaking, walking, swallowing and breathing.19,20In individuals with ALS, high levels of C3 are present at the neuromuscular junction21 where motor neurons communicate directly to muscle cells. Numerous studies suggest that elevated levels of C3 present throughout the motor system of ALS patients are likely to contribute to chronic neuroinflammation and the death of motor neurons.21,22,23 There are no treatments that stop or reverse the progression of ALS, which impacts ~225,000 patients worldwide.24

About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, we aim to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. For more information, please visithttp://apellis.com.

About Sobi Sobi is a specialized international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of hematology, immunology and specialty indications. Today, Sobi employs approximately 1,500 people acrossEurope,North America, theMiddle East,RussiaandNorth Africa. In 2019, Sobi's revenue amounted toSEK 14.2 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi atwww.sobi.com.

1 McKinley C. Extravascular Hemolysis Due to C3-Loading in Patients with PNH Treated with Eculizumab: Defining the Clinical Syndrome. Blood. 2017;130:3471. 2 Sokol RJ, Hewitt S, Stamps BK. Autoimmune haemolysis: an 18-year study of 865 cases referred to a regional transfusion centre.Br Med J (Clin Res Ed).1981;282(6281):2023-2027.National Institute of Health (NIH), Genetic and Rare Diseases Information Center (GARD) 3 Catenion using physician and literature consensus 4 Websitehttps://rarediseases.info.nih.gov/diseases/6130/cold-agglutinin-disease. Accessed November 21, 2019. 5 Berentsen S, Ulvestad E, Langholm R, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients.Haematologica.2006;91(4):460-466. 6 Cold agglutinin disease. Genetic and Rare Diseases Information Center Web site. https://rarediseases.info.nih.gov/diseases/6130/cold-agglutinin-disease. Accessed November 21, 2019. 7 Reynaud Q, Durieu I, Dutertre M, et al. Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies.Autoimmun Rev.2015;14(4):304-313. 8 Dvorak C, et al. Transplant-Associated Thrombotic Microangiopathy in Pediatric Hematopoietic Cell Transplant Recipients: A Practical Approach to Diagnosis and Management. Frontiers in Pediatrics. Vol 7, article 133. (2019) 9 Jodele S, et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood. 124(4): 645653 (2014) 10 Current Uses and Outcomes of Hematopoietic Cell Transplantation (HCT): CIBMTR Summary Slides 11 Passweg et al, BMT. 2019, 38: 15751585 12 Jodele S, et al. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Blood. 135 (13): 10491057. (2020) 13 Noris M, et al. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nature Reviews Nephrology. 8, 622633 (2012) 14 ClearView Analysis using physician and literature consensus. 15 Complement 3 Glomerulopathy (C3G). National Kidney Foundation Website.https://www.kidney.org/atoz/content/complement-3-glomerulopathy-c3g.Accessed November 21, 2019. 16 C3 glomerulopathy. National Institute of Health, Genetics Home Reference.https://ghr.nlm.nih.gov/condition/c3-glomerulopathy#resources. Accessed November 21, 2019. 17 Noris M, Donadelli R, Remuzzi G. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy. Pediatr Nephrol. 2019 Aug;34(8):1311-1323. 18 Cook HT. Evolving complexity of complement-related diseases: C3 glomerulopathy and atypical haemolytic uremic syndrome. Curr Opin Nephrol Hypertens. 2018 May;27(3):165-170. 19 National Institute of Neurological Disorders and Stroke. (2020). Amyotrophic Lateral Sclerosis Fact Sheet. Retrieved from https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Amyotrophic-lateral-Sclerosis-ALS-Fact-Sheet 20 ALS Association. What is ALS? Retrieved June 2020 from https://www.als.org/understanding-als/what-is-als 21 Bahia El Idrissi N, et al. J Neuroinflammation. 2016;13(1):72.4 Sta M, et al. Neurobiol Dis. 2011;42(3):211-220. 22 Woodruff, et al., PNASJanuary 7, 2014111(1)E3-E4 23 Lee, et al Journal of Neuroinflammation volume 15: 171 (2018)25 Arthur K et al. Nat Commun, 2016, Vol 7, article 12408 24 Arthur K et al. Nat Commun, 2016, Vol 7, article 12408

SOURCE: Apellis Pharmaceuticals

See the original post here:
Apellis and Sobi Enter Collaboration for Global Co-development and Ex-US Commercialization of Systemic Pegcetacoplan in Rare Diseases with Urgent Need...

COVID-19 Impact on the Research Antibodies & Reagents Market by Product, Technology, Application, End-user – Global Forecast to 2025 -…

October 27, 2020 08:28 ET | Source: Research and Markets

Dublin, Oct. 27, 2020 (GLOBE NEWSWIRE) -- The "Research Antibodies & Reagents Market by Product (Antibodies (Type, Form, Source, Research Area), Reagents), Technology (Western blotting, Flow Cytometry), Application (Proteomics, Drug Development), End User - COVID-19 Impact - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

The global market projected to reach USD 14.11 billion by 2025 from USD 10.19 billion in 2020, at a CAGR of 6.7% during the forecast period.

The research antibodies and reagents market has evolved owing to factors such as growth in proteomics and genomics research, rising demand for high-quality antibodies for research reproducibility, and increasing R&D activity and expenditure in the life sciences industry. Fueled by the growing demand for personalized medicine and structure-based drug design, the global research antibodies and reagents market is expected to witness significant growth in the coming years.

Based on product, the reagents segment holds the highest market share during the forecast period.

Based on product, the research antibodies and reagents market are segmented into reagent and antibodies. The reagent segment accounted for the larger market share in 2019. The reagents market is experiencing notable growth due to the growing applications of biosciences and biotechnology within the pharmaceutical and healthcare fields.

Based on technology, the flow cytometry segment is expected to register the highest CAGR during the forecast period.

Based on technology, the research antibodies and reagents market is segmented into western blotting, flow cytometry, ELISA, Immunohistochemistry, Immunofluorescence, Immunoprecipitation, and other technologies. The flow cytometry segment is expected to witness the highest growth during the forecast period. This is mainly due to this technique is its ability to perform simultaneous multi-parameter analysis on single cells within a heterogeneous mixture. It offers a high throughput and the automated quantification of cell features. These factors, along with technological innovations in flow cytometry and growing cancer research, are driving the growth of this segment.

By application, the proteomics holds the highest market share during the forecast period.

Based on application, the research antibodies and reagents market is segmented into proteomics, drug development and Genomics. Proteomics held the largest share of the global research antibodies and reagents market in 2019. The growth of the segment is due to as it efficiently maps drug-protein and protein-protein interactions. Moreover, proteomic technologies have minimized the cost, time, and resource requirements for chemical synthesis and biological testing of drugs. Proteomic technologies, such as electrophoresis, ELISA, microarrays, and MS-based proteomics, are highly efficient for analytical laboratory testing.

By end-user, the pharmaceutical & biotechnology holds the highest market share during the forecast period.

The research antibodies and reagents market is segmented into the pharmaceutical & biotechnology companies, academic & research institutions and Contract Research Organizations. The pharmaceutical & biotechnology companies held the largest share of the global research antibodies and reagents end-user market in 2019. The large share of this segment is attributed to the wide use of research antibodies in drug development for the identification and quantification of biomarkers and various analytical procedures.

By Region, The Asia Pacific region is expected to register the highest CAGR during the forecast period.

The Asia Pacific research antibodies and reagents market is expected to grow at the highest CAGR from 2020 to 2025. The growth of this market is primarily due to growing proteomics and genomics research and increasing research funding, investments by pharmaceutical and biotechnology companies, and growing awareness of personalized therapeutics in the region. Also, high-growth countries, such as China, India, Japan, South Korea, Taiwan, Australia, and Singapore are the major contributors to the Asia Pacific research antibodies and reagents market. This region is expected to grow at the highest pace during the forecast period primarily due to growing proteomics and genomics research and increasing research funding, increasing investments by pharmaceutical and biotechnology companies, and growing awareness about personalized therapeutics. Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights 4.1 Research Antibodies and Reagents: Market Overview 4.2 Asia-Pacific: Research Antibodies and Reagents Market, by Application 4.3 Research Antibodies and Reagents Market: Geographic Growth Opportunities 4.4 Research Antibodies and Reagents Market, by Region (2018-2025) 4.5 Research Antibodies and Reagents Market: Developed Vs. Developing Markets

5 Market Overview 5.1 Introduction 5.2 Market Dynamics 5.2.1 Drivers 5.2.1.1 Increasing Research Activity and Funding for R&D 5.2.1.2 Growing Industry-Academia Collaboration 5.2.2 Restraints 5.2.2.1 Quality Concerns and a Lack of Reproducible Results 5.2.3 Opportunities 5.2.3.1 Emerging Markets 5.2.3.2 Personalized Medicine and Protein Therapeutics 5.2.3.3 Growth in Stem Cell and Neurobiology Research 5.2.3.4 Increasing Focus on Biomarker Discovery 5.2.3.5 Rising Interest in Outsourcing 5.2.4 Challenges 5.2.4.1 Cost and Time-Intensive Antibody Development Processes 5.2.4.2 Pricing Pressure Faced by Prominent Market Players

6 Industry Insights 6.1 Introduction 6.2 Industry Trends 6.2.1 Increasing Research on Therapeutic Antibodies 6.2.2 Recombinant Antibodies Are Supporting the Smooth Transition from in Vitro to in Vivo 6.2.3 Growing Consolidation of the Life Science Antibodies and Reagents Market 6.3 Stakeholder Analysis 6.4 Strategic Benchmarking 6.5 Impact of COVID-19 on the Research Antibodies and Reagents Market

7 Research Antibodies and Reagents Market, by Product 7.1 Introduction 7.2 Reagents 7.2.1 Media & Sera 7.2.1.1 Media & Sera Hold the Largest Share of the Reagents Market 7.2.2 Stains & Dyes 7.2.2.1 Growth of the Life Science Industry is Driving the Demand and Use of Stains & Dyes 7.2.3 Fixatives 7.2.3.1 Fixative Agents Are Needed to Preserve the Morphology and Antigenicity of Target Molecules 7.2.4 Buffers 7.2.4.1 Wide Use in Drug Development Will Drive the Market for Buffers 7.2.5 Solvents 7.2.5.1 Organic Solvents See Wide Use in Pharmaceutical Processes and Assays Like Ihc 7.2.6 Enzymes 7.2.6.1 An Increase in Proteomic and Genomic Research Activity Will Ensure Demand for Enzymes 7.2.7 Probes 7.2.7.1 the Versatility, Sensitivity, and Quantitative Capabilities of Probes Have Ensured Their Use in Research 7.2.8 Other Reagents 7.3 Antibodies 7.3.1 Antibodies, by Type 7.3.1.1 Primary Antibodies 7.3.1.1.1 Increasing Demand for Accurate and Reliable Antibodies Follows the Rise in R&D Activity and Expenditure 7.3.1.2 Secondary Antibodies 7.3.1.2.1 Versatility and Low Cost of Production Have Ensured Stable Growth in the Market for Secondary Antibodies 7.3.2 Antibodies, by Form 7.3.2.1 Monoclonal Antibodies 7.3.2.1.1 Monoclonal Antibodies Are Among the Most Common Tools in Biomedical Science 7.3.2.2 Polyclonal Antibodies 7.3.2.2.1 Thermo Fisher Scientific and Abcam Are Major Players in the Polyclonal Antibodies Market 7.3.2.3 Recombinant Antibodies 7.3.2.3.1 Recombinant Antibodies Provide a High-Specificity, High-Sensitivity Option 7.3.3 Antibodies, by Source 7.3.3.1 Mice 7.3.3.1.1 Mice Are the Preferred Hosts for Research-Use Antibody Production 7.3.3.2 Rabbits 7.3.3.2.1 Rabbits Are a Cost-Effective Means of Antibody Production 7.3.3.3 Other Sources 7.3.4 Antibodies, by Research Area 7.3.4.1 Oncology 7.3.4.1.1 the High Prevalence of Cancer Has Boosted Research Activity in the Sector 7.3.4.2 Infectious Diseases 7.3.4.2.1 Rising Awareness and Growing Research Activity Are Key Drivers of the Market 7.3.4.3 Immunology 7.3.4.3.1 Antibodies Are Used to Identify Protein and Peptides to Understand Infectious Disease Immunology Better 7.3.4.4 Neurobiology 7.3.4.4.1 Antibody-Based Approaches Are Widely Used in Molecular and Cellular Neuroscience 7.3.4.5 Stem Cells 7.3.4.5.1 Increasing Funding and the Growing Importance of Stem Cells in Transplantation Are Key Market Drivers 7.3.4.6 Other Research Areas

8 Research Antibodies and Reagents Market, by Technology 8.1 Introduction 8.2 Western Blotting 8.2.1 High Accuracy, Ease of Interpretation, and Other Advantages Have Propelled the Use of Western Blotting 8.3 Flow Cytometry 8.3.1 Flow Cytometry is the Fastest-Growing Technology Segment of the Market 8.4 Enzyme-Linked Immunosorbent Assay 8.4.1 Elisa Has the Potential to Supersede the Current Gold Standard for COVID-19 Testing 8.5 Immunohistochemistry 8.5.1 Complexities of Ihc Pose Challenges to Market Growth 8.6 Immunofluorescence 8.6.1 Immunofluorescence Helps Determine Specific Gene Expressions 8.7 Immunoprecipitation 8.7.1 Results Obtained by Ip Can be Analyzed Through Other Technologies 8.8 Other Technologies

9 Research Antibodies and Reagents Market, by Application 9.1 Introduction 9.2 Proteomics 9.2.1 Proteomics Holds the Largest Share of the Market, by Application 9.3 Drug Development 9.3.1 the Drug Development Applications Segment is Expected to Grow at the Highest Rate 9.4 Genomics 9.4.1 Genomics is Currently An Emerging Area of Research Applications and Expected to See Growth in the Coming Years

10 Research Antibodies and Reagents Market, by End-user 10.1 Introduction 10.2 Pharmaceutical & Biotechnology Companies 10.2.1 Pharma & Biotech Companies Dominate the End-User Market 10.3 Academic & Research Institutions 10.3.1 Growing Government Investments to Propel the Market 10.4 Contract Research Organizations 10.4.1 Growing Work on Monoclonal Antibodies and Drug Conjugates Among Cros is Aiding Market Growth

11 Research Antibodies and Reagents Market, by Region 11.1 Introduction 11.2 North America 11.3 Europe 11.4 Asia-Pacific 11.5 Latin America 11.6 Middle East and Africa

12 Competitive Landscape 12.1 Overview 12.2 Matrix Evaluation Framework 12.3 Research Antibodies Market Share Analysis 12.4 Competitive Leadership Mapping 12.4.1 Stars 12.4.2 Emerging Leaders 12.4.3 Pervasive Companies 12.4.4 Emerging Companies 12.5 Competitive Situation and Trends 12.5.1 Product Launches 12.5.2 Expansions 12.5.3 Acquisitions 12.5.4 Collaborations, Partnerships, and Agreements

13 Company Profiles 13.1 Thermo Fisher Scientific 13.2 Merck Group 13.3 Abcam plc 13.4 Becton, Dickinson and Company 13.5 Cell Signaling Technology 13.6 Bio-Rad Laboratories 13.7 F. Hoffmann-La Roche 13.8 Agilent Technologies 13.9 Danaher Corporation 13.10 Lonza 13.11 Genscript 13.12 PerkinElmer 13.13 Biolegend 13.14 Illumina 13.15 Immunoprecise Antibodies 13.16 Fujirebio Diagnostics Ab 13.17 Analytik Jena Ag 13.18 Omega Bio-Tek 13.19 Dovetail Genomics 13.20 Atlas Antibodies

14 Appendix 14.1 Insights of Industry Experts 14.2 Discussion Guide 14.3 Knowledge Store: Subscription Portal 14.4 Available Customizations 14.5 Related Reports 14.6 Author Details

For more information about this report visit https://www.researchandmarkets.com/r/h35zte

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

See the original post:
COVID-19 Impact on the Research Antibodies & Reagents Market by Product, Technology, Application, End-user - Global Forecast to 2025 -...

RenovaCare to Commence Investor Business and Financial Presentations; Webcast on October 29, 2020 – GlobeNewswire

October 22, 2020 16:35 ET | Source: RenovaCare, Inc.

photo-release

RenovaCare Commences Investor Presentations; Webcast on October 29, 2020 at 11:00 AM EDT

ROSELAND, N.J., Oct. 22, 2020 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; http://www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced that the Company will begin presenting business and financial updates, with the first scheduled for October 29, 2020 at 11:00 a.m. (EDT), to be held via online webcast.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3ab4ca73-7a9f-44f3-93f7-c2dd50571f3a

During the webcast, RenovaCare management will provide an overview of the Companys performance in 2020 year-to-date and also discuss its business objectives for 2021.

Interested investors, analysts and media representatives are invited to participate in the webcast via the following link:

Link to Register for RenovaCare Oct. 29, 2020 Investor Presentation https://edge.media-server.com/mmc/go/RenovaCare10292020

As investor engagement is important to RenovaCare, all interested parties will have the opportunity to ask questions by submitting them to investor_relations@renovacareinc.comby 3:30 p.m. eastern daylight time on October 28, 2020. Shareholders will also have the ability to ask questions during and following the presentation through a chat box with the presentation operator.

The webcast will be recorded and available for playback after the meeting through the RenovaCare website atwww.renovacareinc.com.

RenovaCarepatented investigative technologies are currently in development. They are not available for sale in the United States or elsewhere. There is no assurance that the Companys planned or filed submissions to the U.S. Food and Drug Administration or other regulatory authorities will be accepted or cleared.

About RenovaCare RenovaCare, Inc. is developing first-of-its-kind autologous (self-donated) stem cell therapies for the regeneration of human organs. Its initial product under development targets the bodys largest organ, the skin. The companys flagship technology, the CellMist System, uses its patented SkinGun to spray a liquid suspension of a patients stem cells the CellMist Solution onto wounds.

Over 70 patients with various types of second-degree burns have been treated on an experimental basis utilizing the technology underlying the Companys SkinGun, which RenovaCare has developed as a potential alternative to skin grafting and other treatment options. Sprayed with a gentle mist of their own skin cells, many of these patients left the hospital within days, avoiding generally painful skin graft surgeries and potentially prolonged hospitalization.

RenovaCare is developing its CellMist System as a promising new alternative for patients suffering from burns, chronic and acute wounds, and scars.

For additional information, please call Amit Singh at: 888-398-0202 or visit: https://renovacareinc.com

To receive future press releases via email, please visit: https://renovacareinc.com/investors/register/

Follow us on LinkedIn:https://www.linkedin.com/company/renovacare-inc-/ Follow us on Twitter:https://twitter.com/RenovaCareInc Follow us on Facebook:https://www.facebook.com/renovacarercar

Social Media Disclaimer Investors and others should note that we announce material financial information to our investors using SEC filings and press releases. We use our website and social media to communicate with our subscribers, shareholders and the public about the company, RenovaCare, Inc. development, and other corporate matters that are in the public domain. At this time, the company will not post information on social media that could be deemed to be material information unless that information was distributed to public distribution channels first. We encourage investors, the media, and others interested in the company to review the information we post on the companys website and the social media channels listed below:

* This list may be updated from time to time.

Legal Notice Regarding Forward-Looking Statements No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although RenovaCare, Inc. (the Company) believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words may, will, should, could, expect, anticipate, estimate, believe, intend, or project or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: the timing and success of clinical and preclinical studies of product candidates, the potential timing and success of the Companys product programs through their individual product development and regulatory approval processes, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, obsolescence of the Companys technologies, technical problems with the Companys research, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Companys operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Companys ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, and other risks. There can be no assurance that further research and development will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that the Company will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Companys most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission athttp://www.sec.gov. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Read the original post:
RenovaCare to Commence Investor Business and Financial Presentations; Webcast on October 29, 2020 - GlobeNewswire

Trending Today: COVID-19 Impact on Stem Cell Assay Market Demand, Revenue, Trends, Profit Analysis and Landscape Outlook to 2026 | GE Healthcare,…

Final Report will add the analysis of the impact of COVID-19 On Stem Cell Assay industry

The globalStem Cell Assay marketis expected to witness speedy growth in the forecast period 2020 2026. As per the report added by Syndicate Market Research, market research, and business consulting firm, the Stem Cell Assay market expected to rise with a CAGR of XX% over the forecast period. Presently (2020) the market is estimated at USD XX Million. The report has classified the major key types of Stem Cell Assay along with its applications/end-users and industry segments. Moreover, our researchers have divided the global Stem Cell Assay market into main regions of the market such as Latin America, North America, Asia Pacific, Europe, and the Middle East & Africa.

>>> Get Free PDF Sample Copy of the Report (Including Covid-19 Impact Analysis and TOC):https://www.syndicatemarketresearch.com/sample/stem-cell-assay-market

The report examines several factors that are influencing the industry demand. Factors that are expanding the demand i.e. driving factors are discussed and identified in the scope of the report along with their consequences in the forecast period. Additionally, other factors that are hindering the business demand are analyzed and identified in the report.

COVID-19 Pandemic Analysis

The report forecast the global Stem Cell Assay market to expand xx Million USD in 2019 with a CAGR of xx% during the period 2020-2026 due to the coronavirus circumstances.

The report gives comprehensive coverage of the industry and key market trends with the impact of coronavirus. The report incorporates historical and anticipates market data, demand, price trends, and company shares of the leading geographies. The report splits into the market size (volume and value) based on application, type, and geography.

Leading Organizations/Manufacturers Profiled in the Global Stem Cell Assay Market:GE Healthcare, Promega Corporation, Thermo Fisher Scientific, Merck KGaA, Bio-Rad Laboratories, Bio-Techne Corporation, Cellular Dynamics International, Cell Biolabs, Hemogenix, Stemcell Technologies and many more.

All the above specified top players in the Stem Cell Assay market are profiled based on product portfolio, recent initiatives, revenue, growth rate, business strategies, and gross margin.

The Stem Cell Assay market is Segmented By Type

Dermatology Stem Cell Assay, Cardiovascular Stem Cell Assay, Central Nervous System Stem Cell Assay, Oncology Stem Cell Assay, Other

The Stem Cell Assay market is Segmented By Application

Regenerative Medicine & Therapy Development, Drug Discovery and Development, Clinical Research, Other

Key Regions and Countries are covered in the Global Stem Cell Assay Market as follows:

North America (the USA, Mexico, and Canada) South America (Chile, Brazil, Argentina, and the Rest of South America) Europe (Germany, UK, Italy, France, and the Rest of Europe ) Asia-Pacific (China, Japan, India, Australia, and the Rest of APAC) The Middle East and Africa (South Africa, GCC Countries, Egypt, etc.)

>>> Need More Information about Stem Cell Assay Report, Please Visit@https://www.syndicatemarketresearch.com/market-analysis/stem-cell-assay-market.html

The global Stem Cell Assay market research reports analyzed competitive landscape, import & export, pricing trend, size (value and volume), Share (value and volume), demand-supply analysis, value chain analysis, market opportunities, and risks on a regional and global level. Important regions worldwide are scrutinized the advancements, drivers, restrictions, difficulties, trends influencing the Stem Cell Assay market development over these crucial sectors.

Attributes such as the latest growth in the Stem Cell Assay market with total revenue, sales, government norm, annual production, and trade barriers in some countries mentioned in detail in the report. Stem Cell Assay Report discusses recent product innovations and gives a brief overview of potential regional market shares.

Details of Chapters included in the Stem Cell Assay Market Report:

Chapter 1 and 2:These two chapters render an overview, introduction, and executive summary of the Stem Cell Assay report along with details of the top players in the market

Chapters 3 and 4:These two chapters present an in-depth analysis of the Stem Cell Assay market on a regional and global level, also include its revenue, growth rate, sales, and future opportunities

Chapters 5 and 6:These two chapters cover cost structure analysis, raw material sources, and comprehensive analysis of manufacturing cost. Vendor and Distributor analysis is covered in these two chapters

Chapters 7 and 8:These chapters give a clear insight into the Stem Cell Assay market dynamics. Driving and restraining factors, risks & opportunity analysis

Chapters 9 and 10:Describe all highlights of the Stem Cell Assay market with product specification

Chapter 11:In this chapter, Research methodology and sources for the Stem Cell Assay market study are covered

Chapter 12:It covers Stem Cell Assay market competition, merger, and acquisition on the global and regional level and future prediction

>>> Do Inquiry for the Customization of Stem Cell Assay Market Report:https://www.syndicatemarketresearch.com/inquiry/stem-cell-assay-market

Key Benefits of the Stem Cell Assay Report:

Get detailed COVID-19 pandemic impact & current market condition analysis A whole overview of the Stem Cell Assay market with a brief intro of the research report Get the key players in the market with an analysis of their revenues Global as well as regional analysis with Geographical introduction Definite pictures of market insights and trends SMR research methodology

Note To provide an accurate forecast of the market, all our reports will be updated before dispatch by considering the impact of COVID-19. (*If you have any particular demands, please let us know and we will give you the report as you need.)

About Syndicate Market Research:

Setting a strong foot in the industry with all planned and tactical approaches is surely not a cakewalk. You need loads of research, analysis, take several factors into consideration, and above all, give your valuable time to the entire process. This is where Syndicate Market Research kicks in as a support system for our clients. Our reports targets high growth emerging markets in the USA, Europe, The Middle East & Africa, and Asia Pacific covering industries like IT and Telecommunications, Machinery & Equipment, Electronics & Semiconductor, Chemicals and Materials, Healthcare & Pharma, Energy & Mining, Manufacturing & Construction, Automotive, Food & Beverage, etc.

Get in Touch with Us:

Syndicate Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States +1 347 535 0815 |Email ID:sales@syndicatemarketresearch.com Website:www.syndicatemarketresearch.com |Blog:Syndicate Market Research Blog

More:
Trending Today: COVID-19 Impact on Stem Cell Assay Market Demand, Revenue, Trends, Profit Analysis and Landscape Outlook to 2026 | GE Healthcare,...

Cell Therapy Market 2020 Trends, Size, Share, Growth Opportunities, Emerging Technologies, Regional, Key Players and Forecast to 2025 – Eurowire

Global Cell Therapy Market 2020-2025 is one of the most comprehensive and important additions to Adroit Market Research archive of market research studies. It offers detailed research and analysis of key aspects of the global market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Cell Therapy market. The report also analyzes factors such as drivers, restraints, opportunities, and trends affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides particulars of the competitive landscape for market leaders.

Get sample copy of Cell Therapy Market report @ https://www.adroitmarketresearch.com/contacts/request-sample/611?utm_source=Pranali

Global Cell Therapy market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around global vendors. The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing need for higher productivity. In addition, increasing need for Cell Therapy from APAC is anticipated to boost the growth of the global Cell Therapy market as well.

Top Leading Key Players are:

JCR Pharmaceuticals Co., Ltd., Kolon TissueGene, Inc.; and Medipost and many more.

Browse the complete report @ https://www.adroitmarketresearch.com/industry-reports/cell-therapy-market?utm_source=Pranali

The analysis is likely to create in-depth analysis predicated on preceding questions and comprehensive research regarding the evolution setting, market dimensions, development tendency, performance status and future development tendency of Cell Therapy market on based on saying current position 2020 therefore as to create complete organization and decision on your contest situation and development tendency of global Cell Therapy market and assist brands and investment company to grasp the growth span of the market. Global Cell Therapy market has been divided into product types, application and regions. These segments provide accurate calculations and forecasts for sales in terms of volume and value. This analysis shows a regional development status, including Cell Therapy market size, volume and value, as well as price data.

Global Cell Therapy market is segmented based by type, application and region. Based on Type, the market has been segmented into:

By Use & Type Outlook, (Clinical-use,By Cell Therapy Type,,Non-stem Cell Therapies,Stem Cell Therapies,BM, Blood, & Umbilical Cord-derived Stem Cells,Adipose derived cells,Others), By Therapeutic Area, (Malignancies,Muscoskeletal Disorders,Autoimmune Disorders,Dermatology,Others,Research-use), By Therapy Type, (Allogenic Therapies,Autologous Therapies)

Cell Therapy market study further highlights the segmentation of the Cell Therapy industry on a global distribution. The report focuses on regions of North America, Europe, Asia, and the Rest of the World in terms of developing business trends, preferred market channels, investment feasibility, long term investments, and environmental analysis. The Cell Therapy market report also calls attention to investigate product capacity, product price, profit streams, supply to demand ratio, production and market growth rate, and a projected growth forecast. The Cell Therapy market report provides a detailed analysis of the countries in the region, covering the key challenges, competitive landscape, and demographic analysis, that can help companies gain insight into the country-specific nuances. The analysts have also placed a significant emphasis on the key trends that drive consumer choice and the future opportunities that can be explored in the region than can help companies in revenue expansion. To gain competitive intelligence about leading companies in the sector in the region with information about their market share and growth rates. In addition, the Cell Therapy market study also covers several factors such as market status, key market trends, growth forecast, and growth opportunities. Furthermore, we analyze the challenges faced by the Cell Therapy market in terms of global and regional basis. The study also encompasses a number of opportunities and emerging trends which are considered by considering their impact on the global scale in acquiring a majority of the market share.

For Any Query on the Cell Therapy Market: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/611?utm_source=Pranali

About Us :

Contact Us :

Ryan Johnson Account Manager Global 3131 McKinney Ave Ste 600, Dallas, TX 75204, U.S.A Phone No.: USA: +1 972-362 -8199 / +91 9665341414

Here is the original post:
Cell Therapy Market 2020 Trends, Size, Share, Growth Opportunities, Emerging Technologies, Regional, Key Players and Forecast to 2025 - Eurowire

Cell Culture Protein Surface Coating Market Trends and Analysis Growth by 2025 – The Think Curiouser

Global Cell Culture Protein Surface Coating Market: Snapshot

The global market for cell culture protein surface coatings is slated to expand at a highly promising pace in the next few years, thanks to the vast rise in investments by governments and market players in stem cell research and development activities. Cell culturing is a method used for growing artificial living cells outside the natural environment, under controlled physical conditions. These cells are used to develop model systems for study and research of cellular structures as well as for drug discovery and genetic engineering.

Get Exclusive PDF Sample Copy Of This Report:https://www.tmrresearch.com/sample/sample?flag=B&rep_id=2291

Thus, the growing scope of cell cultures in various applications has led to the development of the 3D cell culture technique, which has been considered one of the key factors responsible for the overall past development of the cell culture protein surface coatings market. Earlier, only a meager percentage of researchers preferred using 3D cell culture technique for drug discovery. However, there has been a dynamic shift from the traditional methods to the current cell culture methods.

Moreover, commercial production of drugs and biologics such as proteins, antibodies, and vaccines using cell culture has helped expand the scope of the latter in the global market. Commercial production has provided extensive business opportunities to manufacturers in the global market. Diverse applications of stem cells such as development of bone grafts and artificial tissue are also expected to fuel the demand for cell culture protein surface coatings over the forecast period. In addition, increasing cell culture applications in toxicology studies and cell-based assays are further pushing the growth of the market.

Global Cell Culture Protein Surface Coating Market: Overview

Cell culture protein surface coatings help in improving cell attachment, growth, and differentiation. They facilitate consistent performance in various cell-based assays and in-vitro culture by improving cell adhesion. A variety of adhesion proteins and other biological materials derived from various sources are being used to enhance performance in cell culture, especially in cell lines that are hard to attach, such as transfected cells. The major types of cell culture are animal-derived protein, human-derived protein, synthetic protein, and plant-derived protein. Good cell attachment has gained increased significance in recent years for improving the recovery of cells from frozen cultures and increasing the stability of attached surfaces. With constant advances in stem cell therapies, a number of advanced protein surface coatings have emerged to study stem cells and to further the potential of regenerative medicine. These developments have positively affected the growth of the global cell culture protein surface coating market.

Buy This Report @https://www.tmrresearch.com/checkout?rep_id=2291<ype=S

Global Cell Culture Protein Surface Coating Market: Key Trends

The increasing focus of numerous biotechnology companies and research laboratories on stem cell research to develop therapies for a range of chronic diseases is a key factor propelling the cell culture protein market. Considerable investment by the governments of various countries to fund several R&D activities related to regenerative medicine has fuelled the market. Coupled with this, the rising demand for biopharmaceutical products such as antibodies, vaccines, and drugs has stimulated the demand for cell culture protein surface coatings. The growing research on stem cells for finding therapies for various cardiovascular and neurological diseases is expected to boost the market in the coming years. The growing prominence of 3D cell culture over 2D cell cultures is expected to unlock exciting opportunities in the cell culture protein surface coating market.

Global Cell Culture Protein Surface Coating Market: Market Potential

The American Heart Association (AHA), together with the Paul G. Allen Frontiers Group, announced in April, 2017 two grantseach worth US$1.5 millionto scientists working on cardiovascular extracellular matrix (ECM) research. Interested researchers have to apply for grants by May 10, and each of the two winners will be entitled to the magnanimous sum.

The ECM regulates all vital cell functions and is considered a highly useful biomaterial for investigators. This can be applied as a stable coating to be used in a variety of cell cultures. The initiative focused on investigating the role of ECM in the initiation and progression of a number of cardiovascular diseases, such as hypertensive heart disease, ischemic heart disease, cardiomyopathies, congenital cardiovascular malformations, and atherosclerosis and vascular diseases. The funding will further the investigation into the diagnosis, prevention, and treatment of cardiovascular diseases. One of the most commonly used protein surface coatings used in ECM is collagen, which facilitates cell adherence, growth, migration, differentiation, and proliferation. The major research initiatives, opine the AHA, will be greatly useful in setting up a new paradigm in research in cell structure in biosciences.

Global Cell Culture Protein Surface Coating Market: Regional Outlook

North America is a prominent market for cell culture protein surface coatings and is expected to exhibit significant growth over the forecast period. The impressive growth in the regional market is attributed to the presence of a robust healthcare infrastructure and considerable advances in stem cell research. In addition, the soaring demand for regenerative medicines for a range of autoimmune therapies is expected to fuel the demand for surface coatings for improving the performance of in-vivo culture.

The Asia Pacific market for cell culture protein surface coating is poised to offer lucrative avenues for players in the market. Favorable regulations forbiologics developmentand a burgeoning biotechnology industry are the factors expected to lead to substantial demand for cell culture protein surface coatings.

Global Cell Culture Protein Surface Coating Market: Competitive Analysis

The market is fairly competitive due to the presence of a large number of regional and global vendors. Leading vendors are actively focused on providing solutions having cell attachment ability and promoting in-vitro cell functions for a variety of cell types to gain competitive edge over others. Leading players operating in this market include Sigma-Aldrich Corporation, Agilent Technologies, Thermo Fisher Scientific, EMD Millipore, Corning Incorporated, Biomedtech Laboratories Inc., Neuvitro Corporation, and Progen Biotechnik GmbH.

To know more about the table of contents, you can click @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=2291

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to busi-ness entities keen on succeeding in todays supercharged economic climate. Armed with an experi-enced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Read more:
Cell Culture Protein Surface Coating Market Trends and Analysis Growth by 2025 - The Think Curiouser

Global Mice Model Market 2019-2020 & Forecast to 2025: Cumulative Impact of COVID-19 on the $2.38 Billion Market – PRNewswire

DUBLIN, Oct. 27, 2020 /PRNewswire/ -- The "Mice Model Market Research Report by Type, by Technology, by Function, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.

The Global Mice Model Market is expected to grow from USD 1,546.85 Million in 2019 to USD 2,398.31 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 7.58%.

Company Usability Profiles:

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Mice Model Market including Charles River Laboratories International, Inc., Cyagen Biosciences, Envigo Ltd, GenOway S.A., Harbour Antibodies Bv, Horizon Discovery Group plc, inGenious Targeting Laboratory, Janvier Labs, Ozgene Pty Ltd, PolyGene, Taconic Biosciences, Inc., The Jackson Laboratory, TransGenic, Inc., and Vivo Bio Tech Ltd..

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Mice Model Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward.

The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information offered by the key players 2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Mice Model Market? 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Mice Model Market during the forecast period? 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Mice Model Market? 4. What is the competitive strategic window for opportunities in the Global Mice Model Market? 5. What are the technology trends and regulatory frameworks in the Global Mice Model Market? 6. What are the modes and strategic moves considered suitable for entering the Global Mice Model Market?

Key Topics Covered:

1. Preface

2. Research Methodology

3. Executive Summary 3.1. Market Outlook 3.2. Type Outlook 3.3. Service Outlook 3.4. Technology Outlook 3.5. Function Outlook 3.6. Application Outlook 3.7. Geography Outlook 3.8. Competitor Outlook

4. Market Overview 4.1. Introduction 4.2. Mice Model Market, By Geography

5. Market Dynamics 5.1. Introduction 5.1.1. Drivers 5.1.1.1. Ongoing innovations in mice models for immune diseases, cancer, and rare diseases 5.1.1.2. Growing consumption of personalized medicine driving the demand for humanized mice models 5.1.1.3. Increasing support in the form of grants & investments and growing pharmaceutical R&D activities 5.1.1.4. Focus of associations on the development of embryonic stem cells as well as knockout and mutant mice 5.1.2. Restraints 5.1.2.1. Increased benefits from cryopreservation 5.1.2.2. Regulations and laws considering the ethical use of animals research 5.1.3. Opportunities 5.1.3.1. Rise of CRISPR as a powerful tool in the field of biomedical research 5.1.3.2. Increasing demand for humanized mice models 5.1.3.3. Increasing monoclonal antibody production 5.1.4. Challenges 5.1.4.1. Availability of alternative methods to animal testing 5.1.4.2. Improvements in zebrafish model development 5.1.4.3. Growing need for improved mice models

6. Market Insights 6.1. Porters Five Forces Analysis 6.1.1. Threat of New Entrants 6.1.2. Threat of Substitutes 6.1.3. Bargaining Power of Customers 6.1.4. Bargaining Power of Suppliers 6.1.5. Industry Rivalry 6.2. Cumulative Impact of COVID-19 6.3. Client Customizations

7. Global Mice Model Market, By Type 7.1. Introduction 7.2. Conditioned/Surgically Modified Mice 7.3. Genetically Engineered Mice 7.4. Hybrid/Congenic Mice 7.5. Inbred Mice 7.6. Outbred Mice 7.7. Spontaneous Mutant Mice

8. Global Mice Model Market, By Service 8.1. Introduction 8.2. Breeding 8.3. Cryopreservation 8.4. Genetic Testing 8.5. Model In-Licensing 8.6. Quarantine 8.7. Rederivation

9. Global Mice Model Market, By Technology 9.1. Introduction 9.2. Microinjection 9.3. Embryonic Stem Cell Injection 9.4. Nuclear Transfer 9.5. Biolistics 9.6. Crispr/Cas9 9.7. Genetically Modified Sperm-Mediated Gene Transfer 9.8. Liposome-Mediated DNA and Electroporation of DNA 9.9. Talens and Zfns 9.10. Virus/Vector-Mediated Gene Transfer

10. Global Mice Model Market, By Function 10.1. Introduction 10.2. Bedding 10.3. Cages 10.4. Feed

11. Global Mice Model Market, By Application 11.1. Introduction 11.2. Cardiovascular Studies 11.3. Central Nervous System Studies 11.4. Diabetes Studies 11.5. Immunology and Inflammation Studies 11.6. Oncology Studies

12. Americas Mice Model Market

13. Asia-Pacific Mice Model Market

14. Europe, Middle East & Africa Mice Model Market

15. Competitive Landscape 15.1. FPNV Positioning Matrix 15.2. Market Ranking Analysis 15.3. Market Share Analysis 15.4. Competitive Scenario

16. Company Usability Profiles 16.1. Charles River Laboratories International, Inc. 16.2. Cyagen Biosciences 16.3. Envigo Ltd 16.4. GenOway S.A. 16.5. Harbour Antibodies Bv 16.6. Horizon Discovery Group plc 16.7. inGenious Targeting Laboratory 16.8. Janvier Labs 16.9. Ozgene Pty Ltd 16.10. PolyGene 16.11. Taconic Biosciences, Inc. 16.12. The Jackson Laboratory 16.13. TransGenic, Inc. 16.14. Vivo Bio Tech Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/a7km2m

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

See the original post here:
Global Mice Model Market 2019-2020 & Forecast to 2025: Cumulative Impact of COVID-19 on the $2.38 Billion Market - PRNewswire